PCM
GALT icon

Pinz Capital Management’s Galectin Therapeutics GALT Stock Holding History

Pinz Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,300
Closed -$20K – 233
2021
Q2 		$20K Buy
+6,300
New +$22.4K 0.01% 361

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinz Capital Management's GALT Position: Q3 2021 in Review

Pinz Capital Management sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 6,300 shares — an estimated $20K sold.

Pinz Capital Management first reported a position in GALT in Q2 2021 and held it in 1 quarter. The position peaked at $20K in Q2 2021. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • Pinz Capital Management reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 6,300 Galectin Therapeutics shares in Q3 2021, an estimated $20K.
  • Pinz Capital Management first reported a position in Galectin Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Galectin Therapeutics position peaked at $20K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.